Lumida
/DXCM
⌘K
Dexcom Inc

Dexcom Inc

DXCM
$83.03USD↓-1.75%-1.48 today

MARKET CAP

31.3B

P/E (TTM)

34.8x

FWD P/E

29.4x

DAY RANGE

$83 – $86

52W RANGE

$54
$93

AI Summary

Stalk
StalkMedium

DXCM is in a Stage 2 corrective phase within an overall uptrend, pulling back into the rising 50-period SMA. Medium-term bias remains bullish as long as the 50 SMA holds. Short-term price is below the 9- and 20-period EMAs, signaling a pause rather than a reversal. Execution should be deferred until a clear bounce or reversal candle off the 50 SMA confirms support. A breakdown below this zone risks a deeper retracement toward the 200-period SMA.

  • ↑Q2 2026 revenue $1.31 B (+13% YoY) driven by global CGM demand
  • ↑Anticipated Medicare coverage for ~12 M type 2 patients expands addressable market
  • ↓Negative earnings yield suggests stock may be overvalued amid competitive pressure
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

DexCom, Inc. (NASDAQ: DXCM) is a leading provider of continuous glucose monitoring (CGM) systems, primarily serving individuals with diabetes. The company has established a competitive edge through innovation and robust market penetration, especially in addressing the growing type 2 diabetes segment. DexCom's products enhance metabolic health and provide critical data for diabetes management, reflecting an ongoing commitment to technological advancements within healthcare. As it evolves, DexCom is closely aligned with the rising demand for digital health solutions and personalized medicine in the diabetes care ecosystem.

Bull says

  • ↑Q2 2026 revenue $1.31 B (+13% YoY) driven by global CGM demand
  • ↑Anticipated Medicare coverage for ~12 M type 2 patients expands addressable market
  • ↑Adjusted EBITDA margin 32.2% and gross margin 64.1% demonstrate strong profitability
  • ↑G7 15-day system adoption accelerates user engagement with longer wear time
  • ↑$1 B share buyback reinforces cash-rich balance sheet and shareholder returns
  • ↑High profitability, robust balance sheet and upward earnings revisions support upside

Bear says

  • ↓Negative earnings yield suggests stock may be overvalued amid competitive pressure
  • ↓Margin risk from higher operational costs, scrap rates and planned hiring
  • ↓G7 rollout faces supply chain and out-of-box failure challenges
  • ↓Delays in CMS approval for non-insulin type 2 users could slow growth
  • ↓Intensifying competition from Abbott and Medtronic may erode market share
  • ↓Negative momentum and elevated leverage raise execution and downside risks

Investment themes with DXCM

Medical Devices↓ -0.50%

Devices and instruments for medical treatment

ISRG · ABT · SYK
Demographics: Elderly Care↓ -0.50%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-24-2026bullish

Transcript signals

Bull points

  • Today we reported second quarter organic revenue growth of 15% compared to the second quarter of 2024.
  • In the U.S., our new customer demand and volume growth remain consistent with the high levels we experienced during the first quarter.
  • as of this month, our type 2 non-insulin reimbursement went live with a third major PBM.

Bear points

  • we do expect the price volume, you know, delta, if you will, to come in a little bit over the course of the year.
  • if it plays out as it's currently written. So let's walk through it. We'll be vocal with you throughout the process. We're obviously staying incredibly close to it.
  • Operating expenses were $474.1 million for Q2 of 2025 compared to $442.7 million in Q2 of 2024.
Read full transcript analysis ›